Tesamorelin: GHRH Analog Research Peptide Guide (2026)

Introduction (research-only scope)

Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that extends its half-life. Unlike most peptides we supply, tesamorelin has an approved pharmaceutical formulation (EGRIFTA, Theratechnologies) authorised by the US FDA for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy^[1]. The material we ship is a research reagent, not the EGRIFTA pharmaceutical product, and is sold strictly for in-vitro laboratory work.

This article summarises GHRH receptor pharmacology, the clinical evidence base that supported FDA approval, the comparison with other GHRH-class peptides in our catalog (CJC-1295, CJC-1295 DAC, sermorelin), and how to verify research-grade purity. Batch-level Certificate of Analysis information is available where applicable and focuses on purity testing.

What is tesamorelin?

Tesamorelin (TH9507) is a synthetic stabilised analog of endogenous human GHRH(1-44). Native GHRH is rapidly degraded in plasma by dipeptidyl peptidase-4 (DPP-4), giving it a half-life of only a few minutes - too short for practical pharmacology. Tesamorelin replaces the N-terminus with a trans-3-hexenoic acid moiety, blocking DPP-4 cleavage and extending the functional half-life to approximately 25-40 minutes - long enough for once-daily research protocols^[2].

Beyond the N-terminal modification, the sequence is identical to native GHRH(1-44), preserving the affinity for the GHRH receptor (GHRH-R) on pituitary somatotrope cells. Because the binding pocket is unchanged, tesamorelin engages the receptor with native pulsatility patterns rather than flooding the system continuously - a pharmacological feature that matters for downstream growth-hormone release biology.

GHRH receptor pharmacology - how tesamorelin works

GHRH-R signalling cascade

The GHRH receptor is a class B G-protein-coupled receptor expressed predominantly on somatotrope cells in the anterior pituitary. Tesamorelin binds the extracellular domain, triggers Gs-protein coupling, activates adenylate cyclase, elevates intracellular cyclic AMP, and ultimately stimulates pulsatile growth-hormone secretion from somatotrope storage vesicles^[2][3].

Why GH pulsatility matters

Native GHRH signalling is pulsatile, with peaks every 3-4 hours. Tesamorelin's 25-40 minute functional half-life preserves that pulsatile pattern rather than producing continuous receptor stimulation. The pulsatility distinction matters because downstream targets - particularly hepatic IGF-1 production - respond differently to pulsatile versus continuous GH exposure^[3].

Downstream IGF-1 and visceral fat effects

In Phase 3 trials supporting the EGRIFTA FDA approval, tesamorelin produced statistically significant reductions in visceral adipose tissue (VAT) measured by CT, accompanied by increases in IGF-1 within the physiological range. The mechanism is consistent with the known GH/IGF-1 axis effects on lipolysis and lean-tissue maintenance^[1][4].

Why hexenoic acid modification

The trans-3-hexenoic acid moiety at the N-terminus blocks DPP-4 cleavage without altering receptor binding. Earlier attempts to extend GHRH half-life relied on amino-acid substitution within the active sequence, which compromised receptor affinity. Tesamorelin's lipid modification was the breakthrough that delivered clinically useful half-life without sacrificing potency^[2].

Approved clinical use vs research-grade material

Tesamorelin is the active pharmaceutical ingredient in EGRIFTA (and EGRIFTA SV), approved by the FDA in 2010 and 2019 respectively for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The approved formulation is a sterile lyophilised powder reconstituted immediately before subcutaneous administration under medical supervision^[1].

The material we supply is not EGRIFTA. It is a research-grade synthesis of the same active sequence, intended for in-vitro laboratory work - receptor-binding assays, second-messenger signalling studies, somatotrope cell-line experiments. It is not a pharmaceutical product, not sterile-filled for human administration, and not authorised for use in patients. The FDA approval of EGRIFTA does not extend to research-grade tesamorelin and does not modify the Research Use Only scope of the reagent material.

Within the EU, the EMA has not authorised tesamorelin as a medicinal product. Research-grade material moves under REACH research-and-development exemptions; it is not regulated as a medicine.

Tesamorelin vs other GHRH-class analogs

We supply four GHRH-class peptides. Each occupies a distinct position on the half-life and structural-modification axes:

• Sermorelin (GHRH 1-29). 29-AA peptide corresponding to the active fragment of native GHRH. Very short half-life (~5-10 minutes). Closest to native GHRH pharmacology; least modified.
• CJC-1295 (without DAC). 29-AA peptide with four amino-acid substitutions that block DPP-4 cleavage. Half-life approximately 30 minutes. Similar functional window to tesamorelin in some respects but structurally different.
• CJC-1295 DAC. Same 29-AA peptide with a maleimidopropionic acid linker that covalently binds plasma albumin (Drug Affinity Complex). Extended half-life of approximately 6-8 days, supporting once-weekly dosing.
• Tesamorelin. 44-AA peptide - the full GHRH(1-44) sequence - with trans-3-hexenoic acid N-terminal modification. Half-life ~25-40 minutes. FDA-approved as EGRIFTA. The most clinically validated GHRH analog in this list.

Choice of GHRH analog in a research protocol depends on the question being asked. Studies of acute receptor pharmacology may benefit from sermorelin's short half-life, which approximates native GHRH; studies of sustained signalling favour CJC-1295 DAC. Tesamorelin sits in the middle and has the most extensive published literature given its approved clinical use.

How to verify research-grade tesamorelin purity

Tesamorelin's 44 amino acids make it considerably more challenging to synthesise than shorter peptides like KPV or GHK-Cu. Standard solid-phase peptide synthesis can introduce deletion sequences, truncations, and side-reaction byproducts that bring nominal HPLC purity below 99% if the synthesis is rushed. Three checks separate research-grade material from substandard product:

1. HPLC purity ≥99% with chromatogram. Sharp main peak with no significant shoulders. Suspiciously round numbers like 99.00% are a fabrication signal.
2. Analytical specification review. Theoretical monoisotopic mass for tesamorelin is approximately 5135 Da. Observed mass should fall within ±1 Da of theoretical.
3. Third-party verification. The CoA should be hosted on the testing lab's platform, not on the supplier's site. Reach out to info@peptralabs.com for the current lot's public verification URL.

The full field-by-field walkthrough is in our Certificate of Analysis guide.

Storage and reconstitution

Tesamorelin's 44-amino-acid length and hexenoic-acid modification make it sensitive to repeated freeze-thaw cycles and surface adsorption. Store the lyophilised vial at -20°C in a desiccant-protected container, or -80°C for archival longer than six months. Equilibrate to room temperature before opening to prevent moisture condensation.

Reconstitute with bacteriostatic water or sterile water for injection. Inject the diluent down the inside wall of the vial rather than directly onto the lyophilised cake, and swirl gently - do not vortex. Aliquot the reconstituted material into low-protein-binding tubes for single-use thawing; the hexenoic-acid moiety adsorbs to glass and to standard polypropylene over time. Reconstituted aliquots at -20°C remain stable for approximately 30 days for receptor-binding work. For the full protocol see our peptide stability and storage guide.

Regulatory status (FDA, EMA, WADA)

FDA. Approved as EGRIFTA (2010) and EGRIFTA SV (2019) for HIV-associated lipodystrophy. Research-grade tesamorelin is outside the scope of the EGRIFTA approval.

EMA. No marketing authorisation. Research material moves under REACH R&D exemptions for in-vitro laboratory use.

WADA. Tesamorelin is listed under Category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) on the 2026 World Anti-Doping Agency Prohibited List, banned in elite sport at any concentration, in and out of competition^[5]. Our full regulatory position across our catalog is documented in the research peptides risk profile.

Why labs choose our tesamorelin

We supply tesamorelin as a research-use material with available purity testing and batch-level CoA information where applicable. The 44-amino-acid synthesis is performed with extended coupling cycles and rigorous intermediate purification to keep deletion-sequence contamination below detection limit. Every order ships same-day from our European warehouse for confirmation before 14:00 Central European Time, with lot-specific CoA archived against your account.

View tesamorelin in our catalog to